Published on January 13, 2010 at 2:49 AM
Theragenics Corporation (NYSE: TGX), a medical device company serving
the surgical products and prostate cancer treatment markets, today
announced that it has signed an agreement with Core Oncology, Inc. for
the distribution of TheraSeed® palladium-103 brachytherapy
seeds. Under the terms of the agreement, Theragenics will be the
exclusive palladium-103 seed supplier to Core for the treatment of
prostate cancer in the U.S. and Canada. The term of the agreement is
through November 30, 2011, and is automatically extended for additional
one-year terms unless terminated by either party upon prior written
notice.
“As one of the largest palladium-103 seed distributors in the U.S. and
an innovator in delivering total brachytherapy solutions to their
customers, Core is a recognized leader in the industry.”
“We are delighted to be partnering with Core as their exclusive supplier
of palladium-103 seeds for prostate cancer treatment in the U.S. and
Canada,” stated M. Christine Jacobs, Chairman and CEO of Theragenics.
“As one of the largest palladium-103 seed distributors in the U.S. and
an innovator in delivering total brachytherapy solutions to their
customers, Core is a recognized leader in the industry.”
“TheraSeed® provides us with the industry’s leading palladium
seed to compliment our industry leading iodine-125 product, ProstaSeed®,”
stated Travis Gay, CEO and President of Core Oncology. “Theragenics is a
recognized leader in brachytherapy and our new partnership should
further Core’s goal of providing high quality and innovative products to
our customers.”
Source: Theragenics Corporation